Johnson & Johnson plans to invest more than $55 billion in U.S.-based manufacturing, research and development, and technology initiatives through 2028—a 25% increase over the company’s previous four-year domestic investment.

The New Brunswick, New Jersey-based healthcare firm broke ground Thursday on a new biologics manufacturing facility in Wilson, North Carolina. The $2 billion project will span 500,000 square feet and is expected to support roughly 5,000 construction jobs and add more than 500 full-time positions upon completion. Company estimates suggest the site will generate $3 billion in economic impact across North Carolina in its first decade of operations.

The Wilson plant is one of four new advanced manufacturing facilities Johnson & Johnson plans to open in the coming years. Additional investments will go toward expanding existing sites within its pharmaceutical and medical technology segments. The company did not specify the locations or timelines for the remaining three facilities.
In a statement, chairman and CEO Joaquin Duato said, “Our increased U.S. investment begins with the groundbreaking of a high-tech facility in North Carolina that will not only add U.S.-based jobs but manufacture cutting edge medicines to treat patients in America and around the world."

The company also said it will increase funding for R&D infrastructure, including work in oncology, neuroscience, immunology, cardiovascular disease, and robotic surgery. Additional spending will target technology that supports drug development, workforce training, and operational efficiency.

Johnson & Johnson reports that its existing U.S. footprint contributes more than $100 billion annually to the domestic economy. With the new investments, the company aims to expand its presence in advanced manufacturing and healthcare innovation.

Further details on site expansions and additional facilities are expected to be announced at a later date.

U.S. Healthcare Homepage